NVIDIA Survey Finds AI Delivering Clear ROI Across Healthcare From Radiology to Drug Discovery

--- headline: "NVIDIA Survey Finds AI Delivering Clear ROI Across Healthcare From Radiology to Drug Discovery" slug: nvidia-ai-healthcare-survey-roi category: research story_number: "11" date: 2026-04-27 authors: - The Vault AI Staff sources: - name: NVIDIA Blog url: https://blogs.nvidia.com/blog/ai-in-healthcare-survey-2026/ - name: Healthcare Digital url: https://healthcare-digital.com/news/nvidia-how-are-70-of-healthcare-organisations-using-ai - name: SiliconANGLE url: https://siliconangle.com/2026/03/18/ai-workforce-now-hirable-nvidia-rewiring-healthcare-inside/ - name: Genetic Engineering & Biotechnology News url: https://www.genengnews.com/topics/artificial-intelligence/nvidia-gtc-2026-agentic-ai-inflection-hits-healthcare-and-life-sciences/ ---

# NVIDIA Survey Finds AI Delivering Clear ROI Across Healthcare From Radiology to Drug Discovery

The healthcare industry has spent years wondering when artificial intelligence would move beyond pilot programs and start paying for itself. According to NVIDIA\u2019s second annual State of AI in Healthcare and Life Sciences survey, that moment has arrived\u2014and the numbers are hard to argue with.

The survey, which polled more than 600 industry professionals across hospitals, pharmaceutical companies, medical device makers, and digital health startups, found that 70% of healthcare organizations are now actively deploying AI in their operations, up from 63% in 2024. More importantly, the investments are translating into measurable business outcomes: 85% of management respondents said AI has increased annual revenue, while 80% reported reduced annual costs.

From Experimentation to Execution

The headline shift in this year\u2019s survey is the transition from AI experimentation to full-scale execution. Healthcare organizations are no longer asking whether AI works\u2014they are asking how fast they can scale it.

Generative AI and large language models now rank as the top workload across the sector, cited by 69% of respondents, a sharp increase from 54% the prior year. Computer vision, long the dominant AI application in healthcare through medical imaging, held steady in second place. Notably, agentic AI\u2014systems in which AI agents autonomously coordinate tasks across workflows\u2014entered the conversation for the first time, with 47% of respondents saying they are either using or actively evaluating AI agents.

Kimberly Powell, NVIDIA\u2019s Vice President of Healthcare, has been vocal about the implications. Powell argues that once health system leaders stop viewing AI as software and start treating it as a workforce asset, the technology could rapidly reduce clinician burnout and expand access to care. She has described agentic AI systems as capable of having \u201can agent call upon another agent, call upon another agent to traverse the otherwise workflow and journey of patients.\u201d

Where the ROI Is Showing Up

The clearest returns are appearing in two areas: medical imaging and drug discovery.

Medical technology companies report the strongest results in imaging, with 57% citing measurable returns from AI-assisted radiology. A full 61% of medtech respondents said they are using AI for medical imaging workflows, where algorithms flag abnormalities, prioritize urgent cases, and reduce the time radiologists spend on routine scans. For a specialty facing chronic workforce shortages\u2014the American College of Radiology has warned of a growing radiologist deficit for years\u2014AI is increasingly positioned not as a luxury but as operational infrastructure.

On the pharmaceutical side, 46% of pharma and biotech respondents identified drug discovery as a top ROI use case. AI models are being deployed across the drug development pipeline, from target identification and molecular screening to predicting clinical trial outcomes. Meanwhile, 55% of pharma and biotech firms reported using agentic AI specifically for literature review, and nearly half are deploying it for drug discovery and biomarker identification. The $4.9 trillion healthcare industry, as Powell has noted, is now deploying AI at more than twice the rate of the broader economy.

Budgets Are Following the Results

Perhaps the most telling signal in the survey is where the money is going. A striking 85% of respondents said their AI budgets will increase in 2026, with 46% planning increases exceeding 10%. Only 3% anticipate cuts\u2014a near-consensus bet on AI\u2019s continued value.

The financial upside is not evenly distributed, however. The survey found that 44% of respondents said AI increased their revenue by more than 10%, but smaller companies appear to be benefiting disproportionately: 56% of small organizations reported revenue growth exceeding 10%, suggesting that AI may be acting as an equalizer that allows nimbler players to compete with entrenched incumbents.

Digital health companies lead overall adoption at 78%, followed by medical technology firms at 74%. Pharma and biotech organizations trail slightly, reflecting the longer timelines and regulatory complexity inherent in drug development. For payers and providers\u2014the hospitals and insurance companies that form the backbone of healthcare delivery\u2014administrative tasks and workflow optimization topped the ROI list at 39%, a reminder that some of AI\u2019s biggest wins may come from reducing paperwork rather than inventing new therapies.

Challenges Remain

The survey is not all optimism. Smaller organizations cite budget constraints (40%) and insufficient training data (33%) as their top barriers to AI adoption. Larger enterprises, meanwhile, point to data privacy and security concerns (39%) and regulatory and ethical issues (37%) as their primary obstacles. The gap suggests that scaling AI in healthcare will require not just better technology but clearer regulatory frameworks and more accessible data infrastructure.

Hybrid computing is also on the rise, with 43% of organizations now using a mix of on-premises and cloud infrastructure for AI projects, up from 35% last year. The trend reflects a pragmatic reality: healthcare data is among the most sensitive in any industry, and many organizations are unwilling to move it entirely to the cloud.

The Bottom Line

NVIDIA\u2019s survey paints a picture of an industry that has crossed an inflection point. The question is no longer whether AI can deliver value in healthcare\u2014it clearly can, and in multiple domains simultaneously. The question now is whether the industry\u2019s regulatory structures, workforce pipelines, and data governance frameworks can keep pace with the technology. For radiologists reading scans faster, researchers screening drug candidates more efficiently, and administrators drowning in less paperwork, the ROI case is already closed. The harder work of making that ROI universal is just beginning.